Research programme: cancer therapeutics - Harbour Biomed

Drug Profile

Research programme: cancer therapeutics - Harbour Biomed

Latest Information Update: 27 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harbour BioMed
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 27 Dec 2016 Harbour Antibodies' transgenic platforms are available for licensing as of 27 Dec 2016.
  • 27 Dec 2016 Harbour BioMed has patent protection for human heavy chain rodent technology and human heavy chain constructs in USA and Europe (Harbour BioMed pipeline, December 2016)
  • 27 Dec 2016 Early research in Cancer in China (Parenteral) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top